Get the Stockscreener App
61.30
0.49%
-0.30
Pre-market:
61.03
-0.27
-0.44%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $61.30, with a volume of 15.13M.
It is down -0.49% in the last 24 hours and up +12.17% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$61.60
Open:
$61.5
24h Volume:
15.13M
Relative Volume:
1.08
Market Cap:
$124.84B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
17.72
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
+2.63%
1M Performance:
+12.17%
6M Performance:
+30.07%
1Y Performance:
+5.31%
1-Day Range:
$60.91
$62.12
1-Week Range:
$59.23
$62.12
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
61.30 | 125.45B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,028.83 | 983.12B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
245.17 | 593.51B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
226.92 | 403.74B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
205.79 | 320.30B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
166.85 | 318.87B | 54.72B | 14.02B | 15.32B | 7.1855 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
RBC Capital Initiates Bristol Myers (BMY) with $60 Target, Cites Late-Stage Pipeline Depth - Finviz
Buybacks Report: Why is Bristol Myers Squibb Company Equity Right stock going upJuly 2025 Selloffs & Daily Profit Maximizing Tips - baoquankhu1.vn
2nd Circ. Skeptical Of Expanding Collectives' Borders - Law360
Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030 - GlobeNewswire Inc.
Why Bristol Myers Squibb Stock Topped the Market Today - AOL.com
Bristol-Myers Squibb Advances Pediatric Lymphoma Combo, Signaling Quiet Upside for BMY Investors - TipRanks
Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal - San Diego Business Journal
RBC initiates Bristol-Myers Squibb stock at Sector Perform, $60 target - Investing.com
FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review - Finviz
Biopharma bites: Layoffs at BMS, Generate's IPO plans, Fortress's voucher sale…and more - FirstWord Pharma
FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation - Yahoo Finance UK
Bristol-Myers Touts Promising Data From Blood Disorder Study - Bitget
Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential - Finviz
Bristol-Myers Squibb’s New Rheumatoid Arthritis Trial: What Early Pipeline Moves Mean for BMY Investors - TipRanks
Bristol-Myers Squibb (BMY) Gets Price Target Raise by Piper Sand - GuruFocus
Bristol Myers Squibb (BMY) Reports Positive Phase 2 Trial Results for Reblozyl - GuruFocus
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 - Investing.com
Piper Sandler raises Bristol-Myers Squibb stock price target to $75 By Investing.com - Investing.com India
Bristol Myers Squibb’s Reblozyl meets trial goals for alpha-thalassemia - Investing.com
BMY: Promising Phase 2 Results for Reblozyl in Alpha-Thalassemia Study - GuruFocus
Large-Cap Stock Analysis 2026: Vertiv, HCA Healthcare, Bristol-Myers SquibbNews and Statistics - IndexBox
China Universal Asset Management Co. Ltd. Purchases New Stake in Bristol Myers Squibb Company $BMY - Defense World
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? - The Motley Fool
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? - The Globe and Mail
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Barclays initiates Bristol-Myers Squibb stock coverage at overweight - Investing.com
Barclays initiates Bristol-Myers Squibb stock coverage at overweight By Investing.com - Investing.com India
ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Finviz
Bristol-Myers Squibb top-products revenues 2024 - Statista
Bristol Myers Squibb (NYSE:BMY) Delivers Stability While S&P 500 Stays Volatile - Kalkine Media
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma - Finviz
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Yahoo Finance
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors - ChartMill
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit - simplywall.st
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Sold by Public Sector Pension Investment Board - MarketBeat
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight – Company AnnouncementFT.com - Financial Times
Iberdomide FDA Milestone Puts Fresh Focus On Bristol Myers Squibb Hematology - Yahoo Finance
U.S. FDA accepts Bristol Myers Squibb's NDA for iberdomide in multiple myeloma - marketscreener.com
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026? - TradingView
Bristol Myers Squibb gains FDA nod for multiple myeloma drug - Traders Union
FDA accepts Bristol Myers Squibb’s new drug application for iberdomide - Investing.com
Vanguard Group Inc. Has $8.84 Billion Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
FDA accepts Bristol Myers Squibb’s new drug application for iberdomide By Investing.com - Investing.com Canada
Bristol-Myers Squibb's Marketing Application for Cancer Therapy Accepted for Review by FDA - marketscreener.com
U.S. Food and Drug Administration accepts Bristol Myers Squibb's new drug application for iberdomide - marketscreener.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):